Simplex™ P with Tobramycin is the original Simplex™ P Bone Cement formula, with the addition of 1g of tobramycin. By maintaining the original formula, surgeons can expect the superior per
For over 35 years, Palacos Bone Cement has clinically proven itself as the gold standard in cemented arthroplasty. And since the introduction of,the Optivac system in 1986, the Palacos/Optivac com
Occu-Flo Plugs Offer: , Easy Insertion , A polished, smooth, transparent finish which creates immediate patient comfort and adaptation , High tolerance by patients , No discomfort should removal be
Inserted into the punctal opening to block tear drainage through the canaliculus, collagen plugs provide temporary relief of dry eye symptoms:, Manufactured from precisely measured premium collagen,
Medicine Products:(Date:12/3/2008)...ewswire/ -- Breast-Specific Gamma Imaging (BSGI) h...than breast MRI in patients with,inconclusive fin...nosis of,breast cancer, according to findings pre...gical Society of North America (RSNA). BSGI is a m...nctive tool to mammography that can identify,lesi...
(Date:12/3/2008)...ond at first not helped by maintenance treatment, ...hDay News) -- Maintenance therapy using low-dose p...hronic hepatitis C who haven,t responded to an ini..., The study also showed a surprising health decli...of four years. , "This course of treatment had ...
(Date:12/3/2008)...l 2% Growth in the Baccalaureate Student Populatio...Capacity , , WASHINGTON, Dec. 3 /PRNewswi...eges of Nursing (AACN) today released preliminary ... baccalaureate nursing programs increased by only ...the eighth consecutive year of enrollment growth, ...
(Date:12/3/2008)... In response to press reports of,...onomy, a nutritional expert,and a leading manufac...stfeed,or use formula responsibly by following th...l that parents refrain from diluting baby formula ...s," said Barbara S. Levine, R.D., Ph.D.,director...
Breaking Medicine News(10 mins):Health News:Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer 2Health News:Hepatitis C Therapy Useless for Some 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 3Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 4Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 5Health News:Cornell Nutritional Expert, Vermont Baby Formula Company Urge Parents Not to Dilute Formula with Extra Water 2...Man seems to rediscover old truths as Australian s...t superbugs such as MRSA.// Scientists at James ...e use of honey by the aborigines (indigenous triba... use honey as a dressing for their wounds. Menti...
...New Delhi: Lt Gen Saibal Mukherjee has taken over ... here Thursday.// An alumnus of Government Medic...my Medical Corps in May 1970. After obtaining MD i... in 1977, he completed training in Radiation Oncol...
...A recent research reports the efficacy of a pharma...ess of metastatic kidney cancer. A comparative stu...that sunitinib is more efficient in halting the pr...he work was published recently in the prestigious ...
...A study published in the March 1st issue of the jo...ep apnea (OSA) are at increased risk for cardiovas...ed link between OSA and cardiovascular disease to ...evalence. Results suggest that OSA plays a potenti...
Other Medicine News:Health News:A New Drug for Halting Metastatic Kidney Cancer 2Health News:Sleep Well, Have a Healthy Heart ! 2(Date:12/3/2008)... 3 Isogen, a contract development ...g, announced it has retained a,strategic financia... global,biopharma demand for Isogen,s services. ,...ul first round series of capital,investment and t...1 2009 to,deliver on the previously unmet process...
(Date:12/3/2008)... Vical Incorporated,(Nas...g letter of intent with EIP,Eczacibasi Ilac Pazar...pany,s,Allovectin-7(R) immunotherapeutic product ...orthern Cyprus. EIP has agreed to obtain the neces...o pay Vical upfront and milestone payments,plus a...
(Date:12/2/2008)...Dec. 2 Biopure Corporati.... Naval Medical Research Center,(NMRC) has submit...vised,investigational new drug (IND) application ...en therapeutic Hemopure(R) [hemoglobin glutamer - ...eatment of trauma patients. The study is,entitled...
(Date:12/2/2008)... 2 Horizon Therapeutics, Inc., a,...nounced that two pivotal,Phase 3 trials evaluatin...501,met all primary endpoints. HZT-501, a novel,...ining ibuprofen and famotidine, demonstrated a,st... of non-steroidal,anti-inflammatory drug (NSAID)-...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Who will recover spontaneously from hepatitis C virus infection 175 1Who will recover spontaneously from hepatitis C virus infection 175 2SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th 238 1Prolexys Pharmaceuticals Initiates Phase 1 Study 157 1Prolexys Pharmaceuticals Initiates Phase 1 Study 157 2Amsterdam Molecular Therapeutics Reports Half Year Results 2007 233 1Amsterdam Molecular Therapeutics Reports Half Year Results 2007 233 2Amsterdam Molecular Therapeutics Reports Half Year Results 2007 233 3Amsterdam Molecular Therapeutics Reports Half Year Results 2007 233 4Amsterdam Molecular Therapeutics Reports Half Year Results 2007 233 5Amsterdam Molecular Therapeutics Reports Half Year Results 2007 233 6Amsterdam Molecular Therapeutics Reports Half Year Results 2007 233 7...e--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncolo...ntation of two,posters at the XIth Annual Internat...rom June 25-28th, 2007. The meeting highlights,imp...of multiple,myeloma. ZIOPHARM is presenting darina...at further elucidates its unique,mechanism of acti...
...sented at the 11th International Myeloma Workshop ...29, 2007,/PRNewswire/ -- The International Myeloma...ding education, advocacy and support,for myeloma p...oday,said that updated statistics reported at the ...nstrate improved survival for a wide,range of myel...
Other Medicine Technology:ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4